orlistat

(redirected from Tetrahydrolipstatin)
Also found in: Medical.
Related to Tetrahydrolipstatin: Orlistat

or·li·stat

 (ôr′lĭ-stăt′)
n.
A drug, C29H53NO5, that reduces dietary fat absorption by inhibiting the enzyme lipase, used in the management of obesity.

[or(tho)- + li(p)stat(in), naturally occurring lipase inhibitor (lip(ase) + -stat + -in).]
American Heritage® Dictionary of the English Language, Fifth Edition. Copyright © 2016 by Houghton Mifflin Harcourt Publishing Company. Published by Houghton Mifflin Harcourt Publishing Company. All rights reserved.

orlistat

(ˈɔːlɪˌstæt)
n
a drug that promotes weight loss
Collins English Dictionary – Complete and Unabridged, 12th Edition 2014 © HarperCollins Publishers 1991, 1994, 1998, 2000, 2003, 2006, 2007, 2009, 2011, 2014
Translations

orlistat

n orlistat m
English-Spanish/Spanish-English Medical Dictionary Copyright © 2006 by The McGraw-Hill Companies, Inc. All rights reserved.
References in periodicals archive ?
This facilitatory effect on mPFC output involved inhibition of synaptic inhibition by engaging endocanna-binoid signaling because CB1 antagonists (AM251 and AM281) and an intracellular inhibitor of diacylglycerol lipase DAGL (tetrahydrolipstatin, THL) blocked the effect of VU0360172 [126, 131].
Mode of action of tetrahydrolipstatin: a derivative of the naturally occurring lipase inhibitor lipstatin.
However, excessive pancreatic lipase inhibition (e.g., tetrahydrolipstatin, Orlistat, Alli), also has several known side effects, including unpleasant gastrointestinal issues--steatorrhea (oily, loose stools with excessive intestinal putrefaction and flatus due to unabsorbed fats reaching the large intestine), fecal incontinence, frequent bowel movements and urgency, compromised absorption of fat-soluble vitamins and nutrients, increased appetite and diminished effectiveness over time.
(73)) A classical DGL inhibitor, tetrahydrolipstatin (THL), inhibited eCB-STD in some studies, (28)), (75)) (-77)) but not in others.
It is a tetrahydrolipstatin, which is a potent, selective, and reversible inhibitor of gastric and pancreatic lipases.
The use of tetrahydrolipstatin (Orlistat)--a pancreatic lipase inhibitor which adds nonabsorbable lipid to the lumen of the intestine by inhibiting lipid absorption--has recently come under scrutiny as a result of alleged adverse effects associated with the ingestion of this drug.
Tetrahydrolipstatin (Orlistat), a commercial anti-obesity drug, is a known pancreatic lipase inhibitor (Borgstrom, 1988; Hadvary et al., 1991).
GlaxoSmithKline Consumer Healthcare anticipates that on January 23, 2006, the FDA's joint Nonprescription Drugs and Endocrinologic and Metabolic Drugs Advisory Committees will review the New Drug Application for proposed over-the-counter use of orlistat (tetrahydrolipstatin) 60(mg) capsules in the U.S., to promote weight loss in overweight adults when used along with a reduced calorie, low-fat diet.
Tetrahydrolipstatin (THL) was a gift of Hoffmann-La Roche (Basel, Switzerland).
Orlistat (Xenical) contains tetrahydrolipstatin, a nonabsorbed inhibitor of gastric and pancreatic lipase.